(1S,2S,4R)-1-(2,2-dimethyl-1,3-dioxalane-4-yl)-propane-1,2-diol | 890053-38-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,2S,4R)-1-(2,2-dimethyl-1,3-dioxalane-4-yl)-propane-1,2-diol
• 英文别名: 1,1-O-(1-methylethyliden)-5-desoxy-L-ribitol；1,2-O-(1-methylethyliden)-5-desoxy-L-ribitol；(1S,2S)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]propane-1,2-diol
• CAS: 890053-38-0
• 化学式: C₈H₁₆O₄
• 分子量: 176.213
• InChiKey: BPVVSRACGYQKRD-XVMARJQXSA-N

物化性质

• 沸点：
  285.4±20.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S,2S,4R)-1-(2,2-dimethyl-1,3-dioxalane-4-yl)-propane-1,2-diol 生成 3,4-O-dibenzyl-1,2-O-(1-methylethylidene)-5-desoxy-L-ribitol
  参考文献：
  名称：

  USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES

  摘要：

  本发明涉及使用黄嘌呤衍生物治疗颅内压增高、继发性缺血以及与细胞毒性活性氧自由基水平升高相关的疾病。

  公开号：

  US20130131071A1
• 作为产物：
  描述：

  D-ribose-4,5-O-(1-methylethyliden)-1,1-ethandiyl dithioacetal 生成 (1S,2S,4R)-1-(2,2-dimethyl-1,3-dioxalane-4-yl)-propane-1,2-diol
  参考文献：
  名称：

  USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES

  摘要：

  本发明涉及使用黄嘌呤衍生物治疗颅内压增高、继发性缺血以及与细胞毒性活性氧自由基水平升高相关的疾病。

  公开号：

  US20130131071A1

文献信息

• USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES
  申请人：VASOPHARM GMBH

  公开号：US20130131071A1

  公开（公告）日：2013-05-23

  The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.

  本发明涉及使用黄嘌呤衍生物治疗颅内压增高、继发性缺血以及与细胞毒性活性氧自由基水平升高相关的疾病。
• Synthesis and bioluminescence-inducing properties of autoinducer (S)-4,5-dihydroxypentane-2,3-dione and its enantiomer
  作者：Manikandan Kadirvel、William T. Stimpson、Souad Moumene-Afifi、Biljana Arsic、Nicola Glynn、Nigel Halliday、Paul Williams、Peter Gilbert、Andrew J. McBain、Sally Freeman、John M. Gardiner

  DOI：10.1016/j.bmcl.2010.02.064

  日期：2010.4

  The autoinducer (4S)-4,5-dihydroxypentane-2,3-dione ((S)-DPD, AI-2) facilitates chemical communication, termed 'quorum sensing', amongst a wide range of bacteria, The synthesis of (S)-DPD is challenging in part due to its instability. Herein we report a novel synthesis of (S)-DPD via (2S)-2,3-O-isopropylidene glyceraldehyde, through Wittig, dihydroxylation and oxidation reactions, with a complimentary asymmetric synthesis to a key precursor. Its enantiomer (R)-DPD, was prepared from D-mannitol via (2R)2,3-O-isopropylideneglyceraldehyde. The synthesized enantiomers of DPD have AI-2 bioluminescenceinducing properties in the Vibrio harveyi BB170 strain. (C) 2010 Elsevier Ltd. All rights reserved.
• WO2006058669A2
  申请人：——

  公开号：——

  公开（公告）日：——
• Aminotetrahydropteridines and processes for manufacture thereof
  申请人：Vasopharm Biotech GmbH

  公开号：EP1669355A1

  公开（公告）日：2006-06-14

  The present invention relates to aminotetrahydropteridines and processes for the manufacture thereof. In particular, the present invention relates to a process for the manufacture of aminotetrahydrobiopterine. Said compound is an inhibitor of NO-synthase and may therefor be a valuable agent in medical applications. The manufacturing process starts from D-ribose, which is transformed in several reaction steps into an open chain osone structure with protected hydroxyl groups. Preferred protective groups are ether forming groups, in particular benzyl groups. Subsequent reaction with tetraaminopyrimidine yields hydroxyl-protected aminopteridines, which, after reduction to aminotetrahydropteridines and cleavage of the protective groups, yield the target compound. The invention also relates to said intermediates and a process for the manufacture thereof. Another subject-matter of the present invention is the use of D-ribose in said manufacturing processes.

  本发明涉及氨基四氢叶酸类化合物及其制造工艺。具体而言，本发明涉及一种制备氨基四氢生物蝶啶的工艺。该化合物是一种NO合酶抑制剂，因此可能在医学应用中是一种有价值的药剂。制造工艺从D-核糖开始，经过几个反应步骤转化为带有保护羟基的开链奥松结构。首选的保护基是醚形成基团，特别是苄基团。随后与四氨基嘧啶发生反应，生成羟基保护的氨基喹啉，经还原成氨基四氢叶酸类化合物并裂解保护基团，最终得到目标化合物。本发明还涉及上述中间体及其制造工艺。本发明的另一个内容是在上述制造工艺中使用D-核糖。